Eton Pharmaceuticals (NASDAQ:ETON) Stock Rating Reaffirmed by HC Wainwright

Eton Pharmaceuticals (NASDAQ:ETON)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report released on Wednesday, Benzinga reports. They presently have a $9.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 95.65% from the stock’s current price.

Eton Pharmaceuticals Stock Performance

Eton Pharmaceuticals stock opened at $4.60 on Wednesday. Eton Pharmaceuticals has a 52 week low of $3.03 and a 52 week high of $5.81. The stock has a market cap of $118.86 million, a price-to-earnings ratio of 115.00 and a beta of 1.29. The company’s 50-day moving average price is $3.75 and its two-hundred day moving average price is $3.73.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its earnings results on Thursday, August 8th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.05). The firm had revenue of $9.07 million for the quarter, compared to the consensus estimate of $10.00 million. Eton Pharmaceuticals had a negative return on equity of 43.62% and a negative net margin of 21.31%.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Westside Investment Management Inc. raised its holdings in shares of Eton Pharmaceuticals by 1.9% in the 1st quarter. Westside Investment Management Inc. now owns 573,960 shares of the company’s stock worth $2,152,000 after purchasing an additional 10,850 shares in the last quarter. Acadian Asset Management LLC grew its position in Eton Pharmaceuticals by 13.7% in the first quarter. Acadian Asset Management LLC now owns 156,386 shares of the company’s stock worth $585,000 after buying an additional 18,898 shares during the last quarter. Victory Capital Management Inc. acquired a new stake in shares of Eton Pharmaceuticals during the 4th quarter valued at $123,000. Renaissance Technologies LLC boosted its stake in shares of Eton Pharmaceuticals by 63.8% during the 2nd quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock worth $350,000 after acquiring an additional 41,469 shares in the last quarter. Finally, Opaleye Management Inc. grew its holdings in shares of Eton Pharmaceuticals by 4.1% in the 4th quarter. Opaleye Management Inc. now owns 2,529,887 shares of the company’s stock worth $11,081,000 after acquiring an additional 99,617 shares during the last quarter. Institutional investors own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.